oblimersen sodium
PreclinicalRNA therapy
oblimersen sodium is a rna therapy that works as a Bcl-2 MRNA Antisense Inhibitor.[2] It is being investigated across 2 indications, with its most advanced program in Preclinical.[1]
oblimersen sodium is one of 83 biologic programs targeting Metastatic Colorectal Cancer. It is currently in Preclinical.
2
Indications
34
Total Trials
0
Active Trials
82
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
282 competitors in Multiple Myeloma
#DrugCompanyPhaseTrials
1Empliciti
Bristol-Myers SquibbPhase 3
Belamaf
GSKPhase 3
Fludara
SanofiPhase 3
TALVEY
Johnson & JohnsonPhase 3
Sarclisa
AAzienda U.S.L. 1 di Massa e Carrara
Phase 3
Biaxin
AbbViePhase 3
Xpovio
KKaryopharm Therapeutics Inc
Phase 3
Azatiq
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Elranatamab
PfizerPhase 3
Vepesid
AAvyxa
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Lymphoma5 trials
Small Cell Lung Cancer3 trials
Acute Myeloid Leukemia3 trials
Colorectal Cancer2 trials
Combination Chemotherapy and Oblimersen in Treating Patients With Advanced Colorectal Cancer
Completed·TThe University of Texas Health Science Center at San Antonio·Phase 1/2·NCT00055822·16 enrolled
17 more indications
Diffuse Large B-Cell Lymphoma2 trials
Multiple Myeloma2 trials
Adenocarcinoma1 trial
Gastrointestinal Stromal Tumor1 trial
Breast Cancer1 trial
Metastatic Renal Cell Cancer1 trial
Hepatocellular Carcinoma1 trial
Chronic Myelogenous Leukemia1 trial
Refractory Solid Tumors1 trial
Macroglobulinemia1 trial
Chronic Lymphocytic Leukemia1 trial
Fluorouracil1 trial
Non-Small Cell Lung Cancer1 trial
Acute Lymphoblastic Leukemia1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for oblimersen sodium. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Bcl-2 MRNA Antisense Inhibitor[2]
- Modality
- RNA therapy[2]
- Highest Phase
- Preclinical[1]
- Company
- NNational Cancer Institute (NCI)